Rev Esp Quimioter 2023;36(Suppl.1):37-45

Current approach to skin and soft tissue infections. Thinking about continuity of care

ROSA BLANES HERNÁNDEZ, MARTÍN RODRÍGUEZ PÉREZ, JUAN FERNÁNDEZ NAVARRO, MIGUEL SALAVERT LLETÍ

Published: 24 November 2023

http://www.doi.org/10.37201/req/s01.10.2023

ABSTRACT
Skin and soft tissue infections are a common reason for patients seeking inpatient and outpatient medical care. Surgery is an essential part of managing in many episodes. Careful evaluation of antibiotic therapy could help clinicians in early identification to patients with treatment failure and to consider an alternative approach or a new surgical revision in “focus control”. With the arrival of new drugs, there is a need to refine the appropriate drug’s decision-making. Drugs with a long half-life (long-acting lipoglycopeptides such as dalbavancin or oritavancin), which allows weekly administration (or even greater), can reduce hospital admission and length of stay with fewer healthcare resources through outpatient management (home hospitalization or day hospitals). New anionic fluoroquinolones (e.g. delafloxacin), highly active in an acidic medium and with the possibility of switch from the intravenous to the oral route, will also make it possible to achieve these new healthcare goals and promote continuity of care. Therefore, management should rely on a collaborative multidisciplinary group with experience in this infectious syndrome.

Rev Esp Quimioter 2023; 36(Suppl.1):37-45 [Full-text PDF]